Literature DB >> 20182528

Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes? The Con Argument.

Michael Camilleri1.   

Abstract

Some claim that symptom-based Rome criteria are diagnostic and enhance clinical practice and choice of therapy for patients presenting with gastrointestinal symptoms. This overview focuses on lower gastrointestinal symptoms: constipation, diarrhea, pain and bloating. The main con arguments for using such criteria for diagnosis are: insufficient specificity, overlap of symptom-based categories or disorders, insufficient and therefore non-specific characterization of pain in the criteria, inability to differentiate the "mimics" of IBS-C and IBS-D, and inability to optimize treatment for IBS-M or bloating in the absence of objective measurements. While doctors may not land in trouble using "symptom diagnosis" of IBS, this should not deter them from optimizing diagnosis and treatment of diseases associated with gastrointestinal dysfunction.

Entities:  

Year:  2009        PMID: 20182528      PMCID: PMC2822078          DOI: 10.1016/j.cgh.2009.10.009

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  45 in total

Review 1.  Chronic constipation.

Authors:  Anthony Lembo; Michael Camilleri
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

Review 2.  The 'con' case. The Rome process and functional gastrointestinal disorders: the barbarians are at the gate!

Authors:  E M M Quigley
Journal:  Neurogastroenterol Motil       Date:  2007-10       Impact factor: 3.598

3.  Diarrhoea associated with idiopathic bile acid malabsorption. Fact or fantasy?

Authors:  E H Thaysen; L Pedersen
Journal:  Dan Med Bull       Date:  1973-12

4.  Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre.

Authors:  R Sadik; P-O Stotzer; M Simrén; H Abrahamsson
Journal:  Neurogastroenterol Motil       Date:  2007-11-05       Impact factor: 3.598

5.  Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit.

Authors:  Anurag Agrawal; Lesley A Houghton; Brian Reilly; Julie Morris; Peter J Whorwell
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

6.  Insights into normal and disordered bowel habits from bowel diaries.

Authors:  Adil E Bharucha; Barbara M Seide; Alan R Zinsmeister; L Joseph Melton
Journal:  Am J Gastroenterol       Date:  2007-11-16       Impact factor: 10.864

7.  Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Authors:  Viola Andresen; Michael Camilleri; Irene A Busciglio; April Grudell; Duane Burton; Sanna McKinzie; Amy Foxx-Orenstein; Caroline B Kurtz; Vineeta Sharma; Jeffrey M Johnston; Mark G Currie; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2007-07-03       Impact factor: 22.682

Review 8.  Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics.

Authors:  A F Hofmann; L R Hagey
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

9.  Differences between painless and painful constipation among community women.

Authors:  Adil E Bharucha; G Richard Locke; Alan R Zinsmeister; Barbara M Seide; Kimberly McKeon; Cathy D Schleck; L Joseph Melton
Journal:  Am J Gastroenterol       Date:  2006-02-08       Impact factor: 10.864

10.  Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry.

Authors:  M Camilleri; A Nadeau; W J Tremaine; J Lamsam; D Burton; S Odunsi; S Sweetser; R Singh
Journal:  Neurogastroenterol Motil       Date:  2009-03-13       Impact factor: 3.598

View more
  11 in total

1.  Irritable bowel syndrome: how useful is the term and the 'diagnosis'?

Authors:  Michael Camilleri
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 2.  Advances in understanding of bile acid diarrhea.

Authors:  Michael Camilleri
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-11-25       Impact factor: 3.869

3.  Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service.

Authors:  Anet Soubieres; Patrick Wilson; Andrew Poullis; Julia Wilkins; Mark Rance
Journal:  Frontline Gastroenterol       Date:  2015-02-24

Review 4.  Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review.

Authors:  William E Whitehead; Douglas A Drossman
Journal:  Am J Gastroenterol       Date:  2010-02-23       Impact factor: 10.864

5.  Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease.

Authors:  Michael Camilleri
Journal:  Gut       Date:  2011-02-02       Impact factor: 23.059

Review 6.  Is irritable bowel syndrome an organic disorder?

Authors:  Magdy El-Salhy; Doris Gundersen; Odd Helge Gilja; Jan Gunnar Hatlebakk; Trygve Hausken
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

7.  Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities.

Authors:  Magdy El-Salhy; Jan Gunnar Hatlebakk; Trygve Hausken
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 8.  Managing irritable bowel syndrome.

Authors:  Joyce K Anastasi; Bernadette Capili; Michelle Chang
Journal:  Am J Nurs       Date:  2013-07       Impact factor: 2.220

9.  Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Authors:  M Camilleri; A Shin; I Busciglio; P Carlson; A Acosta; A E Bharucha; D Burton; J Lamsam; A Lueke; L J Donato; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2014-09-22       Impact factor: 3.598

Review 10.  Sex as a biological variable in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  Neurogastroenterol Motil       Date:  2020-01-13       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.